FDA approves sylvant for multicentric castleman's disease

FDA approves sylvant for multicentric castleman's disease

(HealthDay)—The U.S. Food and Drug Administration has approved Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD), according to a news release issued by the agency today.

The drug is given as an injection and works by blocking a protein that stimulates of immune cells. It is intended for patients with MCD who are not infected with HIV or 8 (HHV-8).

Sylvant was evaluated in 79 participants with MCD who were HIV and HHV-8 negative. The results showed that tumor response was experienced by participants receiving a combination of Sylvant and best supportive care, but not by participants receiving placebo and best supportive care. Itchy skin, weight gain, rash, increased levels of in the blood, and upper were found to be common side effects.

Sylvant was reviewed by the FDA under its priority review program, and the drug has been given orphan product designation as it is intended to treat a rare disease or condition.

"Sylvant is the first FDA-approved drug to treat patients with MCD," Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "Today's approval demonstrates the FDA's commitment to approving drugs for rare diseases."

Sylvant is marketed by Janssen Biotech Inc., based in Horsham, Pa.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Cyramza approved for stomach cancer

Apr 22, 2014

(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Imbruvica approved for mantle cell lymphoma

Nov 13, 2013

(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.

FDA OKs expanded use of prostate cancer drug

Dec 10, 2012

(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food ...

Recommended for you

FDA to start regulating lab-developed tests

3 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments